{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.307","value":"71.72"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"88"}],"units":"Participants"}],"title":"Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.409","value":"-0.73"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"77"}],"units":"Participants"}],"title":"Change at Cycle 2"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.984","value":"-1.04"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"74"}],"units":"Participants"}],"title":"Change at Cycle 4"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"29.984","value":"-1.82"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"62"}],"units":"Participants"}],"title":"Change at Cycle 7"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"30.428","value":"0.40"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"54"}],"units":"Participants"}],"title":"Change at Cycle 10"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"26.585","value":"4.76"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"}],"units":"Participants"}],"title":"Change at Cycle 13"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"34.417","value":"-1.71"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"}],"units":"Participants"}],"title":"Change at Cycle 16"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"25.155","value":"1.76"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"27"}],"units":"Participants"}],"title":"Change at Cycle 19"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"31.707","value":"1.85"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"}],"units":"Participants"}],"title":"Change at Cycle 22"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"45.828","value":"-0.82"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"}],"units":"Participants"}],"title":"Change at Cycle 25"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"40.912","value":"-1.85"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"}],"units":"Participants"}],"title":"Change at Cycle 28"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.280","value":"18.17"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"}],"units":"Participants"}],"title":"Change at Cycle 31"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.313","value":"19.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"}],"units":"Participants"}],"title":"Change at Cycle 34"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.624","value":"15.17"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"}],"units":"Participants"}],"title":"Change at Cycle 37"},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"}],"units":"Participants"}],"title":"Change at Cycle 40"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"26.272","value":"-8.89"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"}],"units":"Participants"}],"title":"End of Treatment"}],"denoms":[{"counts":[{"groupId":"OG000","value":"92"}],"units":"Participants"}],"description":"EQ-5D-3L was a self-administered standardized questionnaire to assess health outcome. It comprised 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. A vertical VAS allows the participants to indicate their health state that day, and ranged from 0 (worst imaginable) to 100 (best imaginable), with higher scores indicating better health state.","dispersionType":"Standard Deviation","groups":[{"description":"Participants with iCCA with tumors harboring FGFR2 gene rearrangements received TAS-120 20 mg tablets orally QD in each of 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.","id":"OG000","title":"Phase 2"}],"paramType":"MEAN","populationDescription":"Analysis was performed on PRO population. Here, 'number analyzed' = number of participants with available data for each specified category.","reportingStatus":"POSTED","timeFrame":"Baseline, Cycle 2, 4, 7, 10, 13, 16, 19, 22, 25, 28, 31, 34, 37, 40 and end of treatment (i.e., Cycle 43 [30 months])","title":"Phase 2: Change From Baseline in EQ-5D-3L Visual Analogue Scale (VAS) at Specified Visits","type":"SECONDARY","unitOfMeasure":"score on a scale"}